Skip to main content

Advertisement

Table 1 Description of the included studies for QoL after EPP or P/D for MPM

From: Systematic review of quality of life following pleurectomy decortication and extrapleural pneumonectomy for malignant pleural mesothelioma

Author(s) Study design Years of data collection Patient (N) Case selection Type of treatment QoL measure QoL measured at: baseline 3 months 6 months 1 year > 2 years Recurrence QAa
EPP
 WEDER, RIBI [29, 30] O (prospective; multi-center) 2000–2003 45 Clinical T1-T3, N0–2; M0, any histology Neo-adjuvant chemo (pre-op; n = 45/61), EPP, radiotherapy (post-op; n = 36/45) Rotterdam Symptoms checklist; SEIQoL y (pre-op) 1, 3 y y   Median 13.5 months 10/12
 AMBROGI [31, 32] O (prospective; single-center) 1997–2007 29 NR EPP, adjuvant chemotherapy and radiotherapy (post-op) SF 36, St George, symptoms, lung function, 6 min walk, cardiac EF, Karnovsky y (pre-op) y y y 2, 3 Median 19.5 months 8/12
 ALVAREZ [33] O (prospective; single-center) 2004–2007 16 (18 no EPP) stage I, II, epithelioid, age < 70 years EPP, chemotherapy, radiotherapy (post-op) ECOG, Karnofsky ECOG 0   y y   18% at 6 months 8/12
 TREASURE [34] RCT (multi-center) 2005–2008 12 (19 no EPP) T1–3, N0–1, M0, any histology Chemotherapy (pre-op), EPP, Radiotherapy (post-op) EORTC C30; LC 13 y (pre-op) 6 weeks, 3 months 6, 9 12, 18 months y 75% at 6 months NA
P/D
 BURKHOLDER [35] (MOLLBERG [36]) O (prospective; single- center) 2010–2011 36 Epithelioid, biphasic WHO PS 0–2 EPD (some talc, neoadjuvant chemotherapy (n = 3), adjuvant chemotherapy (n = 30) EORTC C30, lung function y (pre-op) 4 5, 7, 8    NA 9/12
 SAUTER [37] O (prospective; single-center 1988–1992 20 NR Partial P (some chemotherapy, some radiation; post-op) dyspnea, pain y   y    Median 10 months 9/12
 SOYSAL [38] O (retrospective; single-center) 1974–1992 100 NR 56 P/D; 44 Partial P, chemotherapy (n = 24/100; post-op), radiotherapy (n = 31/100; post-op), chemo + radio (n = 20/100; post-op) dyspnea, pain, cough   y y    Median survival 17 months 4/10
 MARTIN-UCAR [39] O (prospective; single-center) 1997–2001 51 Exclude early stage P/D palliative symptoms y (pre-op) 6 weeks, 3 months y y   53% at 6 months 9/12
 BOLUKBAS [40] O (prospective; single-center) 2010 16 NR radical P, chemotherapy, radiation (post-op) lung function y (pre-op) 2 months     NA 9/12
 RINTOUL [41] RCT (multi-center) 2003–2012 73 NR 73 Partial P, 78 talc, some chemotherapy, radiotherapy (post-op) EORTC C30, LC 13, Euro 5, lung function y (pre-op) 1, 3 y y   Median survival 13 months NA
 TANAKA [42] O (prospective; single-center) 2013–2015 22 NR P/D, some chemotherapy (pre-op) SF-36, lung function y (pre-op)      NA 8/11
 VIGNESWARAN [43] O (prospective; single-center) 2008–2015 114 NR 28 chemotherapy before P/D EORTC C30 y (pre-op) 1 4–5, 7–8 10–11   Median survival 15.21 months 9/12
EPP VS P/D
 RENA [44] O (prospective; single-center) 1998–2009 77 Stage I and II 40 EPP (n = 7 adjuvant chemotherapy; n = 33 neoadjuvant); 37 P/D (n = 6 adjuvant chemotherapy; n = 31 neoadjuvant) EORTC C30 y (pre-op)   y y Median survival 14 and 11 months 8/12
 PLOENES [45] O (retrospective; single-center) NR 48 NR 25 EPP; 23 P/D (intraoperative chemotherapy; n = 6) lung function y (pre-op)   y y Median survival 22 and 29 months 10/12
TOTAL CASES    659           
  1. ECOG Eastern Cooperative Oncology Group Performance Status, EORTC European Organization for Research and Treatment of Cancer, EPD extended pleurectomy and decortication, EPP extrapleural pneumonectomy, MPM malignant pleural mesothelioma, NA not applicable, NR not reported, O observational, P pleurectomy, P/D pleurectomy decortication, PS performance status, RCT randomized controlled trial, SEIQoL-DW Schedule for the Evaluation of Quality of Life-Direct Weighting, QA Quality Assessment, QoL quality of life, QA was not applied to the two RCTs, y yes
  2. aNumber of yes/number of relevant questions from the NIH Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies